Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Metrics to compare | BVXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBVXPPeersSector | |
|---|---|---|---|---|
P/E Ratio | 10.7x | −4.6x | −0.5x | |
PEG Ratio | −1.71 | −0.07 | 0.00 | |
Price/Book | 7.0x | 3.4x | 2.6x | |
Price / LTM Sales | 6.2x | 5.3x | 3.2x | |
Upside (Analyst Target) | 151.6% | 92.0% | 51.2% | |
Fair Value Upside | Unlock | 3.0% | 7.3% | Unlock |